WO2021162554A1 - Moyens et procédés pour déterminer les propriétés des cellules stromales mésenchymateuses - Google Patents

Moyens et procédés pour déterminer les propriétés des cellules stromales mésenchymateuses Download PDF

Info

Publication number
WO2021162554A1
WO2021162554A1 PCT/NL2021/050096 NL2021050096W WO2021162554A1 WO 2021162554 A1 WO2021162554 A1 WO 2021162554A1 NL 2021050096 W NL2021050096 W NL 2021050096W WO 2021162554 A1 WO2021162554 A1 WO 2021162554A1
Authority
WO
WIPO (PCT)
Prior art keywords
msc
cells
fold
markers
hla
Prior art date
Application number
PCT/NL2021/050096
Other languages
English (en)
Inventor
Willem E. Fibbe
Melissa Van Pel
Koen SCHEPERS
Original Assignee
Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP20157519 priority Critical
Priority to EP20157519.8 priority
Application filed by Academisch Ziekenhuis Leiden H.O.D.N. Lumc filed Critical Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Publication of WO2021162554A1 publication Critical patent/WO2021162554A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2301Interleukin-1 (IL-1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/24Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/25Tumour necrosing factors [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells

Abstract

L'invention concerne des moyens et un procédé pour tester des cellules stromales mésenchymateuses (MSC) pour déterminer la qualité, la puissance et/ou la capacité à inhiber une réponse immunitaire, telles que l'inhibition de la prolifération de cellules cibles telles que des lymphocytes T, des lymphocytes B, des cellules NK et d'autres cellules immunitaires et/ou une polarisation de monocytes/macrophages conduisant à une suppression immunitaire directe par la production de médiateurs solubles et l'induction de lymphocytes T régulateurs (T-reg). De tels procédés peuvent comprendre la fourniture d'une MSC ; la culture de ladite MSC en présence et en l'absence d'une ou de plusieurs cytokines choisies parmi : l'interleukine (IL)17A, l'lL-1 bêta, l'oncostatine M (OSM), l'interféron gamma (IFN-gamma), le facteur de nécrose tumorale alpha (TNF-alpha), l'IL-13 et l'IL -4 ; la mise en contact de ladite MSC avec des molécules de liaison qui sont renvoyées à un marqueur spécifique à la MSC et un ou plusieurs parmi : les marqueurs extracellulaires CD54, CD274, l'antigène leucocytaire humain (HLA)-DR, les marqueurs intracellulaires cyclo-oxygénase-2 (COX -2) et l'indoléamine-pyrrole 2,3-dioxygénase (IDO). Un tel procédé peut en outre comprendre la détermination de ladite qualité, la puissance et/ou la capacité à inhiber sur la base de l'expression dudit marqueur spécifique à la MSC et de l'augmentation de l'expression dudit ou desdits un ou plusieurs parmi CD54, CD274, HLA-DR, COX-2 et IDO en réponse à ladite ou auxdites cytosines. L'invention concerne en outre des bibliothèques de cellules, des kits utiles dans et pour des procédés de traitement utilisant la MSC testée.
PCT/NL2021/050096 2020-02-14 2021-02-12 Moyens et procédés pour déterminer les propriétés des cellules stromales mésenchymateuses WO2021162554A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20157519 2020-02-14
EP20157519.8 2020-02-14

Publications (1)

Publication Number Publication Date
WO2021162554A1 true WO2021162554A1 (fr) 2021-08-19

Family

ID=69630203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2021/050096 WO2021162554A1 (fr) 2020-02-14 2021-02-12 Moyens et procédés pour déterminer les propriétés des cellules stromales mésenchymateuses

Country Status (1)

Country Link
WO (1) WO2021162554A1 (fr)

Similar Documents

Publication Publication Date Title
Dutertre et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells
Pereira et al. Sestrins induce natural killer function in senescent-like CD8+ T cells
Xu et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity
JP4714767B2 (ja) ヒト血液由来のcd4+cd25+調節t細胞
Dai et al. CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata
Borchers et al. In vitro assessment of chemokine receptor‐ligand interactions mediating mouse eosinophil migration
Comte et al. Signaling lymphocytic activation molecule family member 7 engagement restores defective effector CD8+ T cell function in systemic lupus erythematosus
KR20140137444A (ko) 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
Blijdorp et al. Expansion of interleukin‐22–and granulocyte–macrophage colony‐stimulating factor–expressing, but not interleukin‐17a–expressing, group 3 innate lymphoid cells in the inflamed joints of patients with spondyloarthritis
De Matteis et al. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
Schmidt-Lucke et al. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy
Llaudo et al. C5aR1 regulates migration of suppressive myeloid cells required for costimulatory blockade‐induced murine allograft survival
Martinez-Murillo et al. CD138 and CD31 double-positive cells comprise the functional antibody-secreting plasma cell compartment in primate bone marrow
Verstegen et al. Inborn errors of adaptive immunity in Down syndrome
Hidalgo et al. The response of T cells to interleukin‐6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue
Kayaba et al. Bone marrow PDGFRα+ Sca-1+-enriched mesenchymal stem cells support survival of and antibody production by plasma cells in vitro through IL-6
Gerstner et al. Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis
US20160130574A1 (en) Methods of measuring gene expression in facs-sorted cells
Laghmouchi et al. Long‐term in vitro persistence of magnetic properties after magnetic bead‐based cell separation of T cells
WO2021162554A1 (fr) Moyens et procédés pour déterminer les propriétés des cellules stromales mésenchymateuses
Shaim et al. Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells
Pontes Ferreira et al. CXCR3 chemokine receptor guides Trypanosoma cruzi-specific T-cells triggered by DNA/adenovirus ASP2 vaccine to heart tissue after challenge
Clay et al. Chemokine networks and in vivo T-lymphocyte trafficking in nonhuman primates
Hussen et al. CD4+ CD8+ T-Lymphocytes in Xenogeneic and Human Graft-versus-Host Disease
Xie et al. Semaphorin 4D Induces an Imbalance of Th17/Treg Cells by Activating the Aryl Hydrocarbon Receptor in Ankylosing Spondylitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21705641

Country of ref document: EP

Kind code of ref document: A1